ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Angelo Maria Minnella, MD, speaks about sozinibercept, a VEGF-C/D inhibitor under development for the treatment of wet age-related macular degeneration.
Used in association with the classic VEGF-A antagonists, this new drug could provide complete protection against VEGF, enhancing the outcomes of treatment.
The phase 3 ShORe and COAST trials are currently ongoing with the aim of demonstrating the superiority of sozinibercept (Opthea) in combination with ranibizumab or aflibercept as compared with ranibizumab or